WA
IRWD icon

Waddell & Associates’s Ironwood Pharmaceuticals IRWD Stock Holding History

Waddell & Associates’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,682
Closed -$41K – 565
2026
Q1 		$41K Buy
+11,682
New +$47.9K ﹤0.01% 446

Other funds holding IRWD

WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return
MFG
Magnus Financial Group New York $1.41B AUM 23.4% 1-Year Est. Return
NAM
NorthCrest Asset Manangement Plymouth, Minnesota $3.89B AUM 40.33% 1-Year Est. Return
RFG
Range Financial Group Tigard, Oregon $366M AUM 76.17% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Waddell & Associates's IRWD Position: Q2 2026 in Review

Waddell & Associates sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2026, closing a stake of 11,682 shares — an estimated $41K sold.

Waddell & Associates first reported a position in IRWD in Q1 2026 and held it in 1 quarter. The position peaked at $41K in Q1 2026. 14 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.

  • Waddell & Associates reported no remaining Ironwood Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Waddell & Associates sold 11,682 Ironwood Pharmaceuticals shares in Q2 2026, an estimated $41K.
  • Waddell & Associates first reported a position in Ironwood Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Waddell & Associates's Ironwood Pharmaceuticals position peaked at $41K in Q1 2026.
  • 14 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.

Based on Waddell & Associates's 13F filing for Q2 2026, filed 15 Jul 2026.